The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
Open accessAbstract
In Brief Objective: To determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy. Background: RAS mutation has been reported to be associated with aggressive tumor biology. However, the effect of RAS mutation on survival and patterns of recurrence after resection of CLM remains unclear. Methods: Somatic mutations were analyzed using mass spectroscopy in 193 patients who underwent single-regimen modern chemotherapy before resection of CLM. The relationship between RAS mutation status and survival outcomes was investigated. Results: Detected somatic mutations included RAS (KRAS/NRAS) in 34 (18%), PIK3CA in 13 (7%), and BRAF in 2 (1%) patients. At a median follow-up of 33 months, 3-year overall survival (OS) rates were 81% in patients with wild-type versus 52.2% in patients with mutant RAS (P = 0.002); 3-year recurrence-free survival (RFS) rates were 33.5% with wild-type versus 13.5% with mutant RAS (P = 0.001). Liver and lung recurrences were observed in 89 and 83 patients, respectively. Patients with RAS mutation had a lower 3-year lung RFS rate (34.6% vs 59.3%, P < 0.001) but not a lower 3-year liver RFS rate (43.8% vs 50.2%, P = 0.181). In multivariate analyses, RAS mutation predicted worse OS [hazard ratio (HR) = 2.3, P = 0.002), overall RFS (HR = 1.9, P = 0.005), and lung RFS (HR = 2.0, P = 0.01), but not liver RFS (P = 0.181). Conclusions: RAS mutation predicts early lung recurrence and worse survival after curative resection of CLM. This information may be used to individualize systemic and local tumor-directed therapies and follow-up strategies. Somatic mutations were analyzed using mass spectrometry in 193 patients who underwent single-regimen modern chemotherapy before resection of colorectal liver metastases (CLM). RAS mutation predicts early lung recurrence and worse survival after curative resection of CLM. This information may be used to individualize systemic and local tumor-directed therapies and follow-up strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 2×
“During the past decade, mutation status of RAS family genes (predominantly KRAS and NRAS) has been shown to correlate with the effectiveness of anti-EGFR agents against unresectable metastatic colorectal cancer,[12, 13] and a possible prognostic role of these somatic gene mutations after resection of CLM in an era pre…”
BackgroundNordlinger, B., Guiguet, M., Vaillant, J.-C., Balladur, P., Boudjema, K., Bachellier, P., Jaeck, D., & Association Française de Chirurgie (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1254::aid-cncr5>3.0.co;2-i · Cited by 1,722
Kopetz, S., Chang, G. J., Overman, M. J., Eng, C., Sargent, D. J., Larson, D. W., Grothey, A., Vauthey, J.-N., Nagorney, D. M., & McWilliams, R. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5278 · Cited by 1,339
Self-citationRees, M., Tekkis, P. P., Welsh, F. K. S., O'Rourke, T., & John, T. G. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31815aa2c2 · Cited by 1,026
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 797
Self-citationBlazer, D. G., Kishi, Y., Maru, D. M., Kopetz, S., Chun, Y. S., Overman, M. J., Fogelman, D., Eng, C., Chang, D. Z., Wang, H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5299 · Cited by 604
Self-citationProfiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 438
Brouquet, A., Abdalla, E. K., Kopetz, S., Garrett, C. R., Overman, M. J., Eng, C., Andreou, A., Loyer, E. M., Madoff, D. C., Curley, S. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6132 · Cited by 396
Self-citationKnijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., Cercek, A., Kemeny, N., D'Angelica, M., Viale, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2994 · Cited by 282
Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0181 · Cited by 234
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217
Shindoh, J., Loyer, E. M., Kopetz, S., Boonsirikamchai, P., Maru, D. M., Chun, Y. S., Zimmitti, G., Curley, S. A., Charnsangavej, C., Aloia, T. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2854 · Cited by 212
Self-citationAndreou, A., Aloia, T. A., Brouquet, A., Dickson, P. V., Zimmitti, G., Maru, D. M., Kopetz, S., Loyer, E. M., Curley, S. A., Abdalla, E. K., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318283a4d1 · Cited by 204
Self-citationNash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0605-3 · Cited by 172 · cited 1×
“During the past decade, mutation status of RAS family genes (predominantly KRAS and NRAS) has been shown to correlate with the effectiveness of anti-EGFR agents against unresectable metastatic colorectal cancer,[12, 13] and a possible prognostic role of these somatic gene mutations after resection of CLM in an era pre…”
BackgroundCejas, P., López-Gómez, M., Aguayo, C., Madero, R., de Castro, J., Belda-Iniesta, C., Barriuso, J., Moreno, V., Larrauri, J., López, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008199 · Cited by 169
Étienne-Grimaldi, M.-C., Formento, J., Francoual, M., François, É., Formento, P., Renée, N., Laurent‐Puig, P., Chazal, M., Benchimol, D., Delpéro, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4906 · Cited by 166
Kim, M. J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J., Bang, S., Park, K. U., Kim, D., Kang, S., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 155
Aloia, T. A., Zorzi, D., Abdalla, E. K., & Vauthey, J. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000171300.62318.f4 · Cited by 150
Self-citationItaliano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114
Oudejans, J. J., Slebos, R. J. C., Zoetmulder, F. A. N., Mooi, W. J., & Rodenhuis, S. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490613 · Cited by 100
Andreou, A., Kopetz, S., Maru, D. M., Chen, S. S., Zimmitti, G., Brouquet, A., Shindoh, J., Curley, S. A., Garrett, C. R., Overman, M. J., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826b4dcc · Cited by 84
Self-citationKRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab
Stremitzer, S., Stift, J., Gruenberger, B., Tamandl, D., Aschacher, T., Wolf, B., Wrba, F., & Gruenberger, T. (2012) · British journal of surgery · doi:10.1002/bjs.8909 · Cited by 82
Perioperative chemotherapy for resectable hepatic metastases
Kopetz, S., & Vauthey, J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60429-8 · Cited by 76
Self-citationMaru, D. M., Kopetz, S., Boonsirikamchai, P., Agarwal, A., Chun, Y. S., Wang, H., Abdalla, E. K., Kaur, H., Charnsangavej, C., Vauthey, J., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181eb2f7b · Cited by 75
Self-citationPredictive and Prognostic Markers in Colorectal Cancer
George, B., & Kopetz, S. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0162-3 · Cited by 71
Self-citationKRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
Kawamoto, Y., Tsuchihara, K., Yoshino, T., Ogasawara, N., Kojima, M., Takahashi, M., Ochiai, A., Bando, H., Fuse, N., Tahara, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.218 · Cited by 38
Cited by
Colorectal cancer liver metastases – a population-based study on incidence, management and survival
Engstrand, J., Nilsson, H., Strömberg, C., Jonas, E., & Freedman, J. (2018) · BMC Cancer · doi:10.1186/s12885-017-3925-x · Cited by 896
Adam, R., de Gramont, A., Figueras, J., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., Sobrero, A., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.006 · Cited by 607
Self-citationSasaki, K., Morioka, D., Conci, S., Margonis, G. A., Sawada, Y., Ruzzenente, A., Kumamoto, T., Iacono, C., Andreatos, N., Guglielmi, A., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002064 · Cited by 472
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Brudvik, K. W., Jones, R. P., Giuliante, F., Shindoh, J., Passot, G., Chung, M. H., Song, J., Li, L., Dagenborg, V. J., Fretland, Å. A., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002319 · Cited by 260
Self-citationYaeger, R., Cowell, E., Chou, J. F., Gewirtz, A. N., Borsu, L., Vakiani, E., Solit, D. B., Rosen, N., Capanu, M., Ladanyi, M., et al. (2015) · Cancer · doi:10.1002/cncr.29196 · Cited by 187
Metadata
- Authors
- Vauthey, J.-N., Zimmitti, G., Kopetz, S. E., Shindoh, J., Chen, S. S., Andreou, A., Curley, S. A., Aloia, T. A., & Maru, D. M.
- Venue
- Annals of Surgery
- Published
- 2013-10
- Volume
- 258
- Issue
- 4
- Pages
- 619-627
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2063985381
- Cited by
- 376
- References
- 32
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.